Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma

Cancer

Volumn 86, Issue 7, 1999, Pages 1189-1197

  Ng, Kenneth K ^a,b   Kris, Mark G ^a   Ginsberg, Robert J ^a   Heelan, Robert T ^a   Pisters, Katherine M W ^a   Miller, Vincent A ^a   Grant, Stefan C ^a   Bains, Manjit ^a   Rusch, Valerie ^a   Rosenzweig, Kenneth E ^a   Martini, Nael ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cisplatin; Induction chemotherapy; Locally advanced disease; Nonsmall cell lung carcinoma

Indexed keywords

CISPLATIN; MITOMYCIN; MVP 400; UNCLASSIFIED DRUG; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; MITOMYCINS; SURVIVAL RATE; VINBLASTINE; VINDESINE;

EID: 0033214864     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1189::AID-CNCR13>3.0.CO;2-N     Document Type: Article

References (37)

1. Damstrup L, Skovgaard PH. Review of the curative role of radiotherapy in the treatment of non small cell lung cancer. Lung Cancer 1994;11:153-78.
2. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr., Green MR. Improved survival in Stage III non-small cell lung cancer: seven-year follow up Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-5.
3. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, et al. Radiation therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a Phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
4. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83: 417-23
5. Martini N, Flehinger B. The role of surgery in N2 lung cancer. Surg Clin North Am 1987:67:1037-49.
6. Martini N, Kris MG, Flehinger BJ, Gralla RJ, Bains MS, Burt ME, et al. Preoperative chemotherapy for Stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993;55:1365-74.
7. Burkes RL, Ginsberg RJ, Shepherd FA, Blackstein ME, Goldberg ME, Waters PF, et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for Stage III unresectable non-small- cell lung cancer: results of the Toronto Phase II trial. J Clin Oncol 1992;10:580-86.
8. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable Stage IIIA non-small cell cancer. J Natl Cancer Inst 1994;86: 673-80.
9. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994;330:153-8.
10. Gralla RJ, Casper ES, Kelsen DP, Braun DW Jr., Dukeman ME, Martini N, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 1981;95:414-20.
11. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6:633-41.
12. Donnadieu N, Paesmans M, Sculier JP. Chemotherapy of non-small cell lung cancer according to disease extent: a meta-analysis of the literature. Lung Cancer 1991;7:243-52.
13. Bhuchar VK, Lanzotti VJ. High dose cisplatin for lung cancer. Cancer Treat Rep 1982;66:375-6.
14. Vogl S, Berenzweig M, Camacho F. Efficacy study of intensive cisplatin therapy in advanced non-small bronchogenic carcinoma. Cancer 1982;50:24-6.
15. Britell J, Eagan R, Ingle J, Creagen ET, Rubin J, Frytak S. cis-dichlorodiammineplatinum(II) alone followed by Adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum(II), Adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung. Cancer Treat Rep 1978;62:1207-10.
16. Rossof AH, Bearden JD III, Coltman CA Jr. Phase II evaluation of Cis-diamminedichloroplatinum in lung cancer. Cancer Treat Rep 1976;66:1679-80.
17. Casper ES, Gralla RJ, Kelsen DP, et al. Phase II trials with high dose cis-dichlorodiammineplatinum (II) in the treatment of non-small cell lung cancer. Cancer Treat Rep 1979; 63:2107-9.
18. Panettiere F, Vance R, Stuckey W, Coltman CA Jr, Costanzi JJ, Chen TT. Evaluation of single-agent cisplatin in the management of non-small cell carcinoma of the lung: a Southwest Oncology Group study. Cancer Treat Rep 1983;67:399-400.
19. Klastersky J, Sculier JP, Bureau G, Libert P, Ravez P, Vandermoten G, et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1989;7:1087-92.
20. DeJager R, Longeval E, Klastersky J. Phase II clinical trials with high dose cisplatin with fluid and mannitol induced diuresis in advanced lung cancer: a Phase II clinical trial of the EORTC Lung Cancer Working Party (Belgium). Cancer Treat Rep 1980;63:1341-6.
21. Gandara D, DeGregorio M, Wold H, Wilbur BJ, Kohler M, Lawrence HJ, et al. High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. a Northern California Oncology Group pilot study in non-small cell lung cancer. J Clin Oncol 1986;4:1787-93.
22. Gandara D, Wold H, Perez E, Deisseroth AB, Doroshow J, Meyers F, et al. Cisplatin dose intensity in non-small cell lung cancer: Phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst 1989;81:790-4.
23. Gralla R, Kris M, Potanovich L, et al. Enhancing the safety and efficacy of the MVP regimen (mitomycin + vinblastine + cisplatin) in 100 patients with inoperable non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1989;8:227.
24. Haedicke K, Camp B, Farber L, et al. Treatment of advanced non-small cell lung cancer (NSCLC) with mitomycin, velban, cisplatin (MVP) at Yale. Proc Am Soc Clin Oncol 1986; 5:183.
25. Livingston R, Griffin B, Higano C, Laramore GE, Rivkin SE, Goldberg RS, et al. Combined treatment with chemotherapy and neutron irradiation for limited non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1987; 5:1716-24.
26. Folman R, Rosman M. The role of chemotherapy in non-small cell lung cancer: the community perspective. Semin Oncol 1988;15:16-21.
27. Spain RC. Neoadjuvant mitomycin C, cisplatin, and infusion vinblastine in locally and regionally advanced non-small cell lung cancer: Problems and progress from the perspective of long-term follow-up. Semin Oncol 1988;15:6-15.
28. Weick J, Crowley J, Natale R, Hom BL, Rivkin S, Coltman CA Jr., et al. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1991;9:1157-62.
29. Ruckdeschel J, Findelstein D, Ettinger D, Creech RH, Mason BA, Joss RA, et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986;4:14-22.
30. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in Stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989;7: 1602-13.
31. Pisters KM, Kris MG, Gralla RJ, Zaman MB, Heelan RT, Martini N. Pathologic complete response in advanced non-small cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol 1993;11: 1757-62.
32. Johnson DH, Einhorn LH, Bartolucci A, Birch R, Omura G, Perez CA, et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 1990;113:33-8.
33. Weisenburger TH, Gail M, Group LCS. Effects of postoperative mediastinal irradiation on completely resected Stage II and Stage III epidermoid cancer of the lung. N Engl J Med 1986;315:1377-81.
34. Mountain CF. A new international staging system for lung cancer. Chest 1986;89:225-33.
35. Kris M, Gralla R, Clark R, Tyson LB, Groshen S. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. Cancer 1987;60:2816-22.
36. Armstrong J, Raben A, Zelefsky M, Burt M, Leibel S, Burman C, et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 1997;44:17-22.
37. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.